CA2664430A1 - Analogues de medicaments contre le vih immunochimiquement equivalents - Google Patents
Analogues de medicaments contre le vih immunochimiquement equivalents Download PDFInfo
- Publication number
- CA2664430A1 CA2664430A1 CA002664430A CA2664430A CA2664430A1 CA 2664430 A1 CA2664430 A1 CA 2664430A1 CA 002664430 A CA002664430 A CA 002664430A CA 2664430 A CA2664430 A CA 2664430A CA 2664430 A1 CA2664430 A1 CA 2664430A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- group
- analog
- phenyl
- coor5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- AIDS & HIV (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86344206P | 2006-10-30 | 2006-10-30 | |
| US60/863,442 | 2006-10-30 | ||
| US86598007A | 2007-10-02 | 2007-10-02 | |
| US11/865,980 | 2007-10-02 | ||
| PCT/EP2007/009389 WO2008052737A2 (fr) | 2006-10-30 | 2007-10-30 | Analogues de médicaments contre le vih immunochimiquement équivalents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2664430A1 true CA2664430A1 (fr) | 2008-05-08 |
Family
ID=39327012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002664430A Abandoned CA2664430A1 (fr) | 2006-10-30 | 2007-10-30 | Analogues de medicaments contre le vih immunochimiquement equivalents |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2094660A2 (fr) |
| JP (1) | JP2010508250A (fr) |
| CA (1) | CA2664430A1 (fr) |
| WO (1) | WO2008052737A2 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010132852A2 (fr) * | 2009-05-15 | 2010-11-18 | Amplyx Pharmaceuticals Inc. | Inhibiteurs de protéase |
| DE102009041443A1 (de) * | 2009-09-16 | 2011-03-31 | Archimica Gmbh | Salze des 6-Chlor-4-(cyclopropylethinyl)-1,4-dihydro-4-(trifluormethyl)-2H-3,1-benzoxazin-2-ons und deren Synthese, Aufreinigung und Anwendung als Vorstufen für Efavirenz |
| CA2796620A1 (fr) * | 2010-06-04 | 2011-12-08 | North-West University | Formulation injectable |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030100088A1 (en) * | 2001-07-13 | 2003-05-29 | Sigler Gerald F. | Protease inhibitor conjugates and antibodies useful in immunoassay |
| US7193065B2 (en) * | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
-
2007
- 2007-10-30 WO PCT/EP2007/009389 patent/WO2008052737A2/fr not_active Ceased
- 2007-10-30 EP EP07819430A patent/EP2094660A2/fr not_active Withdrawn
- 2007-10-30 CA CA002664430A patent/CA2664430A1/fr not_active Abandoned
- 2007-10-30 JP JP2009533751A patent/JP2010508250A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010508250A (ja) | 2010-03-18 |
| WO2008052737A3 (fr) | 2009-01-22 |
| EP2094660A2 (fr) | 2009-09-02 |
| WO2008052737A2 (fr) | 2008-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7482437B2 (en) | Protease inhibitor conjugates and antibodies useful in immunoassay | |
| EP2467139B1 (fr) | Immunoessai de l imatinib | |
| CA2239224C (fr) | Dosage immunologique de topiramate, analogues et anticorps | |
| WO2006102200A2 (fr) | Immunodosage du docetaxel | |
| US20030100088A1 (en) | Protease inhibitor conjugates and antibodies useful in immunoassay | |
| CA2664430A1 (fr) | Analogues de medicaments contre le vih immunochimiquement equivalents | |
| EP1809672B1 (fr) | Conjugues d'atazanavir et anticorps utiles dans un dosage immunologique | |
| US6992177B1 (en) | Saquinavir derivatives useful in immunoassay | |
| US20070178544A1 (en) | Anti fk778antibodies and high sensitive immunoassay methods | |
| US6291198B1 (en) | Antibody that recognizes pyrazine derivative and method for measuring 1,2-dicarbonyl derivative using said antibody | |
| JP3161513B2 (ja) | ピラゾスルフロン誘導体、抗ピラゾスルフロンエチル抗体、それを分泌するハイブリドーマ、及びピラゾスルフロンエチルの分析方法 | |
| KR19980026589A (ko) | 메탐페타민(methamphetamine)에 대한 특이항체 분비세포주 | |
| HK1119181A (en) | Atazanavir conjugates and antibibodies useful in immunossay | |
| HK1116864B (en) | 5-fluoro-uracil immunoassay | |
| HK1147800A (en) | 5-fluoro-uracil immunoassay | |
| HK1116864A1 (en) | 5-fluoro-uracil immunoassay | |
| HK1147799B (en) | 5-fluoro-uracil immunoassay | |
| HK1116250B (en) | Docetaxel immunoassay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |